Rocket Pharmaceuticals
RCKT
120 hedge funds and large institutions have $1.18B invested in Rocket Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 41 increasing their positions, 27 reducing their positions, and 8 closing their positions.
350% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 8
112% more capital invested
Capital invested by funds: $555M → $1.18B (+$621M)
52% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 27
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
30% more funds holding
Funds holding: 92 → 120 (+28)
0.36% less ownership
Funds ownership: 94.74% → 94.38% (-0.36%)
10% less call options, than puts
Call options by funds: $765K | Put options by funds: $846K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$9.95M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.29M |
| 3 |
DM
Deerfield Management
New York
|
+$6.52M |
| 4 |
HM
HealthCor Management
New York
|
+$6.49M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.98M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.78M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$3.33M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.87M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.44M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
HSBC Holdings
London,
United Kingdom
| – | -$125K | -10,687 | Closed |
|
|
TRCT
127
Tower Research Capital (TRC)
New York
| – | -$50K | -4,250 | Closed |
|
128
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$2K | -150 | Closed |
|
RCKT Hedge Fund Activity: Q4 2019 in Review
120 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2019, worth a combined $1.18B — up 112% from $555M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new RCKT positions and 8 closed out — a net gain of 28 holders — while 41 added to existing stakes and 27 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $9.95M. The largest seller was Sphera Funds Management, cutting an estimated $4.98M.
- 120 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2019, up from 92 in Q3 2019.
- Funds reported $1.18B of Rocket Pharmaceuticals stock for Q4 2019, up 112% quarter-over-quarter.
- 36 funds opened new Rocket Pharmaceuticals positions in Q4 2019 and 8 closed out, a net change of +28 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2019 was Lord, Abbett & Co, an estimated $9.95M added.
- The largest Rocket Pharmaceuticals seller in Q4 2019 was Sphera Funds Management, an estimated $4.98M sold.
Based on aggregated 13F filings for Q4 2019.